Canada's Xenon Pharma reports bigger-than-expected net loss in Q4 due to high R&D expenses

Overview

• Canada-based biopharma's Q4 net income was $105.3 million

• Net loss for Q4 increased due to higher R&D expenses

• Company's pro forma cash of $716 mln extends runway into H2 2027

Outlook

• Xenon anticipates topline data for Phase 3 X-TOLE2 study in March 2026

• Company expects NDA submission for azetukalner in second half of 2026

• Xenon projects sufficient cash to fund operations into second half of 2027

Result Drivers

• R&D EXPENSES - Increase in R&D expenses driven by Phase 3 clinical studies of azetukalner in epilepsy and neuropsychiatry

• EARLY-STAGE PROGRAMS - Co advancing early-stage programs for pain with novel ion channel modulators

• CASH RUNWAY - Pro forma cash of $716 mln extends runway into H2 2027

Company press release: ID:nGNX5zppGB

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 21 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the biotechnology & medical research peer group is "buy"

• Wall Street's median 12-month price target for Xenon Pharmaceuticals Inc is $55.00, about 23.4% above its February 25 closing price of $44.58

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)